Jamjoom Pharmaceuticals Factory Company
Jamjoom Pharmaceuticals Factory Company scores highest on Earnings (92) and lowest on Price (21). Its PosiPenta is 66.06 out of 100, better than most similar companies.
Compared with similar companies in the Healthcare sector in Saudi Arabia.
The five pillars
Details
PPrice
| P/E ratio | 17.31 |
| P/B ratio | 4.43 |
EEarnings
| Trailing EPS | ₹173.93 |
| Forward EPS | — |
NNitro
| Price | 3010.24 |
| 52-week high | 4144.45 |
| 52-week low | 2977.32 |
| Fall from 52-week high | 27.4% |
TTorque
| Return on equity (ROE) | 27.00% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | 0.35 |
| Market cap | ₹21,071 Cr |
| Insider holding | 61.39% |
| Dividend yield | 3.46% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Jamjoom Pharmaceuticals Factory Company's PosiPenta score?
Jamjoom Pharmaceuticals Factory Company's PosiPenta is 66.06 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Which PosiPenta pillar is strongest for Jamjoom Pharmaceuticals Factory Company?
Earnings (growth), with a score of 92 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Jamjoom Pharmaceuticals Factory Company?
Price (valuation), with a score of 21 out of 100: weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.